Evidence map›Paper›PMID 21922329›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2011

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test.

Jonas B Møller, William J Jusko, Wei Gao, Torben Hansen, Oluf Pedersen, Jens J Holst, Rune V Overgaard, Henrik Madsen, Steen H Ingwersen

Open access · greenAbstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jonas B MøllerQuantitative Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark. jbem@novonordisk.com
William J Jusko
Wei Gao
Torben Hansen
Oluf Pedersen
Jens J Holst
Rune V Overgaard
Henrik Madsen
Steen H Ingwersen
Novo Nordisk (Denmark) · DKDorn Research Institute · USUniversity at Buffalo, State University of New York · USTechnical University of Denmark · DKUniversity of Copenhagen · DK

Funding

MATHEMATICAL MODELS IN PHARMACODYNAMICSR01GM057980 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JUSKO, WILLIAM J., KRZYZANSKI, WOJCIECH · 1998 to 2013
$3.4M
NIGMS NIH HHS GM 57980NIGMS NIH HHS R01 GM057980
6 · The paper itself

Abstract

GLP-1 is an insulinotropic hormone that synergistically with glucose gives rise to an increased insulin response. Its secretion is increased following a meal and it is thus of interest to describe the secretion of this hormone following an oral glucose tolerance test (OGTT). The aim of this study was to build a mechanism-based population model that describes the time course of total GLP-1 and provides indices for capability of secretion in each subject. The goal was thus to model the secretion of GLP-1, and not its effect on insulin production. Single 75 g doses of glucose were administered orally to a mixed group of subjects ranging from healthy volunteers to patients with type 2 diabetes (T2D). Glucose, insulin, and total GLP-1 concentrations were measured. Prior population data analysis on measurements of glucose and insulin were performed in order to estimate the glucose absorption rate. The individual estimates of absorption rate constants were used in the model for GLP-1 secretion. Estimation of parameters was performed using the FOCE method with interaction implemented in NONMEM VI. The final transit/indirect-response model obtained for GLP-1 production following an OGTT included two stimulation components (fast, slow) for the zero-order production rate. The fast stimulation was estimated to be faster than the glucose absorption rate, supporting the presence of a proximal-distal loop for fast secretion from L: -cells. The fast component (st₃) = 8.64·10⁻⁵ [mg⁻¹]) was estimated to peak around 25 min after glucose ingestion, whereas the slower component (st₄ = 26.2·10⁻⁵ [mg⁻¹]) was estimated to peak around 100 min. Elimination of total GLP-1 was characterised by a first-order loss. The individual values of the early phase GLP-1 secretion parameter (st₃) were correlated (r = 0.52) with the AUC(0-60 min.) for GLP-1. A mechanistic population model was successfully developed to describe total GLP-1 concentrations over time observed after an OGTT. The model provides indices related to different mechanisms of subject abilities to secrete GLP-1. The model provides a good basis to study influence of different demographic factors on these components, presented mainly by indices of the fast- and slow phases of GLP-1 response.

Indexed as

Models, StatisticalAdultBlood GlucoseDiabetes Mellitus, Type 2Enteroendocrine CellsFastingGlucagon-Like Peptide 1Glucose Tolerance TestHumansInsulinMiddle AgedBlood GlucoseGlucagon-Like Peptide 1Insulin

Identifiers

PMID21922329
PMCPMC3407884
OpenAlexW2045493461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.